Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Neuroblastoma
Preliminary Results From the Sloan-kettering Clinical Study
July 22nd, 2007
Preliminary results from the immunotherapeutic cancer study at Memorial Sloan-Kettering Cancer Center show a very good safety profile for SBG. Furthermore, encouraging responses on cancer development have been observed among several patients that have been treated with SBG in combination with the monoclonal antibody against neuroblastoma. In line with the timetable described in the company's report for the 1st quarter 2007, all 24 patients have now been included in the clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC). In this study, SBG is tested in combination with a monoclonal antibody (3F8) against the cancer form neuroblastoma. The patients are...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
